FDA Class I Medical Device Recalls by the Numbers (2026)

When the U.S. Food and Drug Administration (FDA) monitors a medical device corrective action or removal, the agency assigns a classification based on the level of clinical risk. Among these, Class I recalls are the most severe, representing situations in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death. Across the entire FDA medical device recall enforcement database, comprising 39,430 enforcement reports all-time through July 2026, Class I actions represent a small but critical minority—just 3,576 records, or 9.1% of the database.

However, this raw percentage obscuring a far more concentrated risk landscape. Class I recalls are not evenly distributed across the medical device industry. Instead, they are heavily concentrated within a few life-support, critical-care, and high-volume sterile-supply categories, and are driven by a relatively small cohort of manufacturing firms. For biopharma operators, quality directors, hospital procurement teams, and regulatory specialists, understanding the macro trends, recalling firms, and specific failure modes within this high-risk database is vital for managing device supply chains and mitigating clinical risk.

This analysis provides a comprehensive, data-anchored breakdown of 3,576 FDA Class I medical device recall records. By analyzing text-mined device descriptions, identifying corporate consolidation patterns, tracing historical yearly waves, and detailing recent safety alerts, we present a granular view of device safety and FDA enforcement strategy heading into late 2026.

---

How does Class I recall distribution compare across all device recalls?

To establish a baseline, we must examine how Class I recalls sit within the broader context of all FDA medical device recall classifications. The FDA database logs recalls under three classes:

• Class I (High Risk): 3,576 records (9.1%) — Reasonable probability of serious adverse health consequences or death.
• Class II (Moderate Risk): 34,828 records (88.3%) — Exposure may cause temporary or medically reversible adverse health consequences, or the probability of serious adverse health consequences is remote.
• Class III (Low Risk): 1,025 records (2.6%) — Exposure is not likely to cause adverse health consequences.
• Not Yet Classified: 1 record (<0.1%)

Class II recalls represent the overwhelming majority of database records, reflecting moderate-risk events such as labeling modifications, non-sterile packaging defects on non-critical instruments, and software updates for diagnostics. Class III recalls are rare, typically covering minor administrative anomalies.

The 3,576 Class I records represent the "sharp end" of device failures. In these cases, a device malfunction directly threatens a patient's immediate physiology. When an infusion pump stops flowing, a patient may experience sudden hemodynamic collapse. When a ventilator software error causes a screen freeze, a patient in respiratory distress may suffer from hypoxia. Because of these stakes, active hardware and invasive catheters occupy a disproportionately large share of the Class I database.

For a comparative look at drug recalls, which follow a different regulatory structure, see our analysis on drug recalls by the numbers: FDA enforcement analysis.

---

What categories of devices drive the most Class I recalls?

To identify where the highest clinical risks lie, we keyword-categorized the product descriptions and recall reasons across all 3,576 Class I records. This keyword mapping reveals that over half of all Class I recalls occur in just three primary areas: procedure convenience packs, vascular-access catheters, and respiratory care.

The table below breaks down the Class I database by text-mined device categories:

Data Source: FDA Medical Device Recall Database. Keyword categorization of 3,576 Class I records. Due to overlapping descriptors, category counts are illustrative and not strictly additive.

Analyzing the Category Leaders

1. Procedure Kits & Convenience Packs (19.5%): This category leads Class I recalls due to the nature of sterile packaging. A convenience pack (e.g., a "laparotomy pack" or an "open-heart tray") is assembled by a third-party packaging firm that bundles sterile components from multiple manufacturers. If a single component within that tray—such as a syringe, a gown, or a suture—is recalled by its original manufacturer due to a sterility breach, the packaging firm must recall the entire convenience pack. This generates separate recall records in the FDA database for every pack configuration containing the affected component, inflating the total record count.
2. Vascular Access & Catheters (15.9%): Catheters and central lines are inserted directly into the major blood vessels. If a catheter breaks, cracks, or peels, it can release fragments into the bloodstream, leading to embolization, vessel occlusion, or cardiac arrest. Consequently, catheter material defects almost always trigger Class I classifications.
3. Ventilators & Respiratory (14.6%): Ventilator malfunctions are categorized as Class I because the patient population is unable to breathe independently. Software freezes, battery depletion alarms that fail, or material degradation in breathing circuits directly lead to oxygen deprivation and respiratory failure.
4. Combination Products and Drug-Delivery Hardware: Infusion pumps (9.0%) and diabetes hardware (1.3%) fall under the combination product or drug-delivery umbrella. Active drug-delivery hardware represents a high concentration of Class I recalls compared to its overall volume. A temporary pump failure directly interrupts life-sustaining medications, making these devices highly sensitive to Class I classifications. For a deep dive into the infusion pump segment, read our post on drug-delivery device recalls: infusion pumps 3.4x more likely to be Class I.

---

Which firms lead Class I medical device recalls?

A firm-level breakdown of the 3,576 Class I recalls reveals a highly concentrated landscape. The table below details the top recalling firms, with legal-entity variants consolidated under their parent corporate names:

Data Source: FDA Medical Device Recall Database (2001–2026). Legal entities (e.g., "Medtronic Vascular" and "Medtronic CRHF") are consolidated. Post-acquisition entities (Teleflex and Arrow International, Medline LP and Medline Northfield) are combined to show true corporate footprint.

Understanding the Firm Leaderboard

1. Customed, Inc. (412 records): Based in Puerto Rico, Customed is a major contract packager that compiles customized surgical and procedural trays for hospitals. The company’s high recall count is driven by sterile packaging issues and component recalls. If a supplier recalls a single component, Customed must issue individual recall notices for every customized kit variant containing that item, generating hundreds of database entries.
2. Medtronic (346 records): Medtronic’s footprint spans multiple business units. Medtronic Vascular (203 recalls) and Medtronic Cardiac Rhythm and Heart Failure (143 recalls) are market leaders in high-risk implantable cardiology and interventional vascular access. The size of Medtronic's installed base, combined with the safety-critical nature of pacemakers, ICDs, and stenting systems, means that product corrective actions are frequently classified as Class I.
3. Teleflex / Arrow International (249 records): Teleflex acquired Arrow International in 2007, combining two of the largest vascular-access portfolios in healthcare. The combined count includes Teleflex LLC (129), Arrow International Inc. (42), Arrow International LLC (39), and Teleflex Medical (39). The recalls are dominated by central venous catheters, hemodialysis kits, and PICC lines where packaging defects or catheter material breakdown occurred, posing a risk of air embolism or catheter fragmentation.
4. Philips Respironics (80 records): Philips’ recall history is dominated by the multi-year mechanical ventilator and CPAP recall, where sound-abatement PE-PUR foam was found to degrade into toxic particles and gases, posing an inhalation and carcinogenic risk. This massive corrective action generated dozens of individual Class I records for different models and configurations.
5. Medline Industries (144 records): Comprising Medline Industries LP (72) and Medline Industries LP - Northfield (72), this company operates a high-volume custom sterile convenience kit business similar to Customed, generating multiple records whenever a single tray component is recalled.

When assessing these totals, quality managers should keep in mind that high recall counts are often correlated with market share. A large installed base naturally increases the probability of identifying component issues. Furthermore, companies with mature, transparent quality systems are more proactive in self-reporting and initiating recalls for minor component defects.

---

What is the yearly trend of Class I recalls (2006-2026)?

Recall volume is not stable year-over-year. It fluctuates based on technology cycles, industry manufacturing shifts, and changes in FDA enforcement intensity. The chart below traces Class I recalls by their initiation date from 2006 through mid-2026:

Year | Class I Recall Records
2006 | 3
2007 | 1
2008 | 1
2009 | 1
2010 | 0
2011 | 16
2012 | 88   [==]
2013 | 189  [=====]
2014 | 554  [===============]
2015 | 75   [==]
2016 | 112  [===]
2017 | 120  [===]
2018 | 98   [==]
2019 | 368  [==========]
2020 | 159  [====]
2021 | 171  [====]
2022 | 177  [====]
2023 | 584  [================]
2024 | 314  [========]
2025 | 377  [==========]
2026*| 168  [====]
(*2026 is partial-year data through mid-July)

The historical series contains three major surges:

1. The 2014 Peak (554 records): Driven by industry-wide FDA inspections targeting sterile convenience pack assemblers and custom tray manufacturers, forcing major packaging firms to log separate recalls for hundreds of custom kit part numbers.
2. The 2023 Peak (584 records): The highest year in the registry. This peak was driven by software defects and battery failures in infusion pumps, CPAP machines, and implantable cardiac pacemakers, reflecting the FDA’s post-pandemic enforcement backlog clearance.
3. The 2025 Surge (377 records): FDA officials have acknowledged a notable increase in Class I recalls in 2025. At the 2026 MedCon conference, FDA Office Director Anne Reid of the Office of Medical Device and Radiological Health Inspectorate (OMDRHI) noted that Class I recalls had risen roughly 232% between 2020 and 2025, telling attendees, "This is not a trend we're happy about."

It is worth noting that different reporting methodologies yield varying counts for 2025:

• The FDA’s "Most Serious Medical Device Recalls" web page lists 111 recalls and early alerts for 2025 (a count focused on unique recall events and primary product lines).
• Industry analyses (such as Rivel and RAPS) cite approximately 376 confirmed Class I recalls.
• Our analysis of the FDA Medical Device Recall Enforcement database, which counts individual enforcement report records by initiation date, yields 377 entries.

These numbers demonstrate the importance of tracing database metrics directly to their specific sources and methodologies rather than relying on generalized averages.

---

What are the key Class I case anchors from 2025-2026?

To understand how the FDA applies Class I classifications, we can examine three high-profile case anchors from the 2025–2026 dataset:

1. Abiomed Impella CP Set with SmartAssist (May 2026)

• Device Type: Vascular access and temporary cardiac support pump (combination device).
• The Issue: Abiomed (a Johnson & Johnson company) recalled the Impella CP Set with SmartAssist (10th Generation) and associated introducer kits due to a risk that the catheter tip could fracture or damage the vessel wall during insertion, or that the pump could experience sudden loss of purge pressure.
• Regulatory Status: Classified as Class I because a loss of cardiac support in a patient undergoing cardiogenic shock is immediately life-threatening. This event showcases the overlap between vascular access and cardiac rhythm implants.

2. Arrow International / Teleflex Catheter and Line Kits (April 2026)

• Device Type: Vascular access catheters (PICC, Hemodialysis, and Epidural kits).
• The Issue: Arrow International recalled multiple catheter kits—including Pressure Injectable Arrowg+ard Blue PICC kits, Hemodialysis catheter kits, and Epidural catheter kits—due to issues with packaging seals that compromised tray sterility, as well as reports of catheter hub cracking.
• Regulatory Status: Classified as Class I because a non-sterile line inserted directly into a central vein carries a high risk of systemic sepsis, and catheter cracking can lead to air embolisms or device fragment loss in the bloodstream.

3. Medline Convenience Kits (May 2026)

• Device Type: Procedure kits & convenience packs.
• The Issue: Medline recalled multiple convenience kits, including adult central line insertion trays and open heart cardiac surgery trays, because they contained drapes and syringes that had been recalled by their primary manufacturers.
• Regulatory Status: Classified as Class I because utilizing a compromised central line tray during surgery poses a risk of bacterial contamination, and surgical tray components must maintain absolute sterility to prevent deep surgical site infections.

---

Recommendations for Clinical Quality and Procurement Teams

Given the high concentration of Class I recalls in sterile trays, vascular access, and active drug-delivery hardware, hospital procurement and clinical quality teams should implement the following steps:

1. Establish a Multi-Tiered Recall Triage Workflow: Hospitals must not wait for physical manufacturer recall letters, which can take weeks to arrive. Quality teams should establish an automated lookup against the FDA Medical Device Recall database to screen inventory weekly. For a template on how to design this, read our guide on FDA drug recall lookup and pharmacy triage workflows.
2. Audit Convenience Pack Sterility Trails: When purchasing custom sterile procedure trays (from Customed, Medline, or other convenience packagers), request the manufacturer's sterility certificate and verify the origin of critical tray components. Ensure the CDMO or contract packer has a robust component-recall tracking system.
3. Monitor Material Integrity of Vascular Access Devices: In service lines using Arrow/Teleflex, Medtronic, or Cook catheters, monitor insertion failures and catheter cracks. Report any material defects to the FDA's MedWatch system and the manufacturer's quality team immediately.
4. Confirm Global Establishment Compliance: Verify that your critical device suppliers manufacture their items in FDA-registered facilities with a clean history of inspection reports. For a global breakdown of registered device facilities, see our analysis on FDA registered device establishments by country (2026).

---

Frequently Asked Questions

What makes a device recall Class I versus Class II or III?

The FDA classifies recalls based on clinical severity. A Class I recall is issued when there is a reasonable probability that using or being exposed to the device will cause serious adverse health consequences or death. A Class II recall covers moderate risks where exposure may cause temporary or medically reversible problems. A Class III recall applies when the device is unlikely to cause any health issues but violates a labeling or manufacturing regulation.

Why do convenience packs and surgery trays lead Class I recall counts?

Procedure convenience packs (assembled by custom packagers like Customed or Medline) bundle dozens of individual sterile components (scalpels, drapes, syringes, sutures) from different suppliers. If a single supplier recalls one of these components, the custom packager must issue a recall notice for every procedural kit configuration that contains it. This creates a high volume of individual recall records in the FDA database, even though they stem from a single component issue.

How does the FDA's Class I list differ from our database count?

The FDA's public-facing "Most Serious Medical Device Recalls" web page lists unique recall actions and primary product lines (e.g., 111 entries in 2025). In contrast, the FDA's Medical Device Recall Enforcement database logs individual records for every affected product code, model number, and lot. Our database analysis of 377 Class I records for 2025 counts these individual enforcement entries, which provides a more granular view of supply-chain impact.

How does corporate consolidation affect recall counts?

Many medical device brands are acquired but continue to operate under their original names. For example, Arrow International is a subsidiary of Teleflex, and Hospira's pump lines are owned by ICU Medical. When analyzing recalls, consolidating these subsidiaries under their parent corporations (such as combining Arrow and Teleflex to show 249 recalls, or Medline LP and Medline Northfield to show 144 recalls) is necessary to understand a manufacturer's true safety footprint.

Where can I check if a medical device is under recall?

Providers can search the official FDA Medical Device Recalls Database using the manufacturer's name, the device brand, the model number, or the specific lot number. The openFDA Device Recalls API also provides queryable access to these records, allowing hospitals to integrate automated recall checking into their inventory management software.

---

Sources

1. U.S. Food and Drug Administration (FDA). Medical Device Recalls and Early Alerts Database. Center for Devices and Radiological Health (CDRH). FDA Recalls Search
2. openFDA Device Enforcement Reports API. U.S. Food and Drug Administration. openFDA Device Enforcement JSON API
3. Regulatory Affairs Professionals Society (RAPS). MedCon 2026: FDA sees uptick in Class I recalls in 2025 as it tackles resourcing issues. RAPS MedCon Coverage
4. National Institutes of Health (NIH) / PubMed Central (PMC). A Comprehensive Analysis of Class I Medical Device Recalls: Patterns, Causes and Global Impacts. PMC Article PMC11416579
5. Medical Device and Diagnostic Industry (MD+DI) Online. The Devices FDA Doesn't Want You Using: April Edition (2026 recalls). MD+DI Article
6. U.S. Code of Federal Regulations. 21 CFR Part 7 — Enforcement Policy. U.S. Government Publishing Office. CFR Part 7
7. Abiomed, Inc. (J&J). Urgent Medical Device Correction — Impella CP Set with SmartAssist (May 22, 2026). Abiomed Recall Bulletin
8. Teleflex Incorporated. Arrow Vascular Catheter Recall Notifications (April 2026). Teleflex Safety Alerts